AVORO CAPITAL ADVISORS LLC
Q2 2023 Form 13-F
NEW YORK, NEW YORK
CIK 0001633313
· CRD 154091
· SEC-registered investment adviser
$7.4B Reported Value Total
AVORO CAPITAL ADVISORS LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $7,777,370,092, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
4 funds
· $14.0B gross asset value
Hedge Fund: $13.4B · Venture Capital Fund: $647.5M
Source: Form ADV filed 2026-03-05
Reported value
$7.4B
Quarter over quarter
+4.6%
Holdings
43
Top-10 concentration
69.1%
Key People
Form ADV owners & control persons
Behzad Aghazadeh
MEMBER
Neil Cammarosano
CHIEF FINANCIAL OFFICER
Scott Andrew Epstein
CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2023 13F record
Q2 2023 13F filing summary
| Period of report | June 30, 2023 |
|---|---|
| Filed | August 14, 2023 |
| Form | 13F-HR |
| Reported value | $7.4B |
| Positions | 43 |
| Change in reported value | +9.3% |
| New positions | 6 |
| Exited positions | 1 |
| Position turnover | 15.9% |
| Top-10 concentration | 69.1% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
26 | $11.1B |
|
Q1 2026 13F
Filed May 15, 2026
|
30 | $10.2B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
33 | $10.2B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
30 | $7.7B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
30 | $5.7B |
|
Q1 2025 13F
Filed May 15, 2025
|
33 | $6.4B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
39 | $7.1B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
35 | $6.9B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
41 | $7.5B |
|
Q1 2024 13F
Filed May 15, 2024
|
46 | $8.6B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
42 | $7.2B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
45 | $6.4B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
43 | $7.4B |
|
Q1 2023 13F
Filed May 15, 2023
|
38 | $6.7B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
36 | $6.7B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
39 | $5.4B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
40 | $5.1B |
|
Q1 2022 13F
Filed May 16, 2022
|
43 | $5.5B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
40 | $5.9B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
43 | $6.4B |
27 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | APLS APELLIS PHARMACEUTICALS INC | $1.0B | 13.73% |
| 2 | HZNP HORIZON THERAPEUTICS PLC | $720.0M | 9.77% |
| 3 | UTHR UNITED THERAPEUTICS CORP | $642.4M | 8.71% |
| 4 | SRPT SAREPTA THERAPEUTICS INC | $530.0M | 7.19% |
| 5 | ARGX ARGENX SE | $492.4M | 6.68% |
| 6 | MDGL MADRIGAL PHARMACEUTICALS INC | $350.0M | 4.75% |
| 7 | BMRN BIOMARIN PHARMACEUTICAL INC | $346.7M | 4.7% |
| 8 | FOLD AMICUS THERAPEUTICS INC | $344.1M | 4.67% |
| 9 | SGEN SEAGEN INC | $338.7M | 4.59% |
| 10 | ASND ASCENDIS PHARMA | $319.6M | 4.34% |
| 11 | ISEE IVERIC BIO INC | $316.7M | 4.3% |
| 12 | KRYS KRYSTAL BIOTECH INC | $300.6M | 4.08% |
| 13 | ALNY ALNYLAM PHARMACEUTICALS INC | $209.9M | 2.85% |
| 14 | MRTX MIRATI THERAPEUTICS INC | $200.7M | 2.72% |
| 15 | XENE XENON PHARMACEUTICALS INC | $188.7M | 2.56% |
| 16 | CBAY CYMABAY THERAPEUTICS INC | $112.8M | 1.53% |
| 17 | DICE DICE THERAPEUTICS INC | $102.2M | 1.39% |
| 18 | KYMR KYMERA THERAPEUTICS INC | $88.6M | 1.2% |
| 19 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | $88.0M | 1.19% |
| 20 | BCRX BIOCRYST PHARMACEUTICALS INC | $84.9M | 1.15% |
Values as reported on the Q2 2023 Form 13F. Every position is in the holdings table below.